AbbVie (ABBV) DECNUPAZ Wins FDA Approval for Rare Blood Cancer BPDCN

The U.S. Food and Drug Administration approved AbbVie's (ABBV) DECNUPAZ for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer, the company announced May 28, 2026. The CD123-targeted therapy demonstrated a 70% complete remission rate in a pivotal clinical trial. BPDCN affects approximately 1,000 patients annually in the U.S., with limited treatment options previously available. AbbVie shares rose 1.2% in pre-market trading following the decision. The approval strengthens AbbVie's oncology portfolio, adding a new hematology asset alongside blockbusters Imbruvica and Venclexta. DECNUPAZ is expected to launch commercially in the third quarter of 2026, the company said.